



CODEN [USA]: IAJPB

ISSN: 2349-7750

**INDO AMERICAN JOURNAL OF  
PHARMACEUTICAL SCIENCES**Available online at: <http://www.iajps.com>

Research Article

**FORMULATION AND INVITRO EVALUATION OF  
HYDROCODONE ORAL SUSTAINED RELEASE TABLETS**Bhupathi Ashish Rahul<sup>1</sup>, Dr. V. Anjaneyulu<sup>2</sup>, Dr. G. Vijaya Kumar<sup>3</sup><sup>1,2</sup>KGR Institute of Technology and Management, Rampally, Kesara, Rangareddy,  
Telangana, India<sup>2</sup>Professor and Head, Dept. of Pharmacy, KGR Institute of Technology and Management,  
Rampally, Kesara, Rangareddy, Telangana, India**Abstract:**

*The aim of the present study was to develop an sustained release formulation of Hydrocodone to maintain constant therapeutic levels of the drug for over 8 hrs. Various grades of eudragit and HPMC were employed as polymers. Hydrocodone dose was fixed as 4 mg. Total weight of the tablet was considered as 100 mg. Polymers were used in the concentration of 10mg and 20mg concentration. All the formulations were passed various physicochemical evaluation parameters and they were found to be within limits. Whereas from the dissolution studies it was evident that the formulation (F3) showed better and desired drug release pattern i.e., 98.43 % in 12 hours. It followed zero order release kinetics mechanism.*

**Keywords:** Hydrocodone, Eudragit, HPMC, Sustained release tablets.**Corresponding author:**

**Dr. Gampa Vijaya Kumar,**  
Professor and Head, Dept. of Pharmacy,  
KGR Institute of Technology and Management,  
Rampally, Kesara, Rangareddy,  
Telangana, India  
Email ID: [vijaytanu71@gmail.com](mailto:vijaytanu71@gmail.com)

QR code



Please cite this article in press as Gampa Vijaya Kumar et al., *Formulation and Invitro Evaluation of Hydrocodone Oral Sustained Release Tablets*, Indo Am. J. P. Sci, 2017; 4(12).

**INTRODUCTION:**

Sustained release dosage forms are designed to release a drug at a predetermined rate in order to maintain a constant drug concentration for a specific period of time with minimum side effects [1-3].

Hydrocodone is a narcotic analgesic related to codeine, but more potent and more addicting by weight. It is used also as cough suppressant. To reduce the number of doses and to increase patient compliance it was formulated as sustained release tablets.

**MATERIALS AND METHODS:**

Hydrocodone, HPMC K4M, HPMC K15M, HPMC K100M, Eudragit L 100, Eudragit S 100, Eudragit

RSPO, MCC pH 102, Magnesium stearate, PVP K30 Cellulose chemicals were Laboratory grade made of SD Fine chemicals Pvt Ltd

**Formulation of Hydrocodone Dispersible Tablet by Direct- Compression:**

Composition of preliminary trials for Hydrocodone Dispersible Tablet by direct compression is shown in table 3.5. All the ingredients were weighed. Required quantity of drug and excipient mixed thoroughly in a polybag. The blend is compressed using rotary tablet machine-8 station with 6mm flat punch, B tooling. Each tablet contains 2.5 mg Hydrocodone and other pharmaceutical ingredients.

**Table 1: Formulation of Hydrocodone sustained release matrix tablets**

INGREDIENT	F <sub>1</sub>	F <sub>2</sub>	F <sub>3</sub>	F <sub>4</sub>	F <sub>5</sub>	F <sub>6</sub>	F <sub>7</sub>	F <sub>8</sub>	F <sub>9</sub>	F <sub>10</sub>	F <sub>11</sub>	F <sub>12</sub>
Hydrocodone	10	10	10	10	10	10	10	10	10	10	10	10
HPMC K4M	10	20	-	-	-	-	-	-	-	-	-	-
HPMC K15M	-	-	10	20	-	-	-	-	-	-	-	-
HPMC K100M	-	-	-	-	10	20	-	-	-	-	-	-
Eudragit L-100	-	-	-	-	-	-	10	20	-	-	-	-
Eudragit S 100	-	-	-	-	-	-	-	-	10	20	-	-
Eudragit RSPO	-	-	-	-	-	-	-	-	-	-	10	20
PVP K30	5	5	5	5	5	5	5	5	5	5	5	5
Magnesium Stearate	2	2	2	2	2	2	2	2	2	2	2	2
MCC	73	63	73	63	73	63	73	63	73	63	73	63

**NOTE:** All ingredients are expressed in mg only for a total weight of 100mg


**Evaluation of prepared tablets**

The designed formulation tablets were studied for their physicochemical properties like weight variation, hardness, thickness, friability, *In-vitro* release and drug content.

**RESULTS AND DISCUSSION:****Standard Calibration curve of Hydrocodone:****Table 2: Concentration and absorbance obtained for calibration curve of Hydrocodone in 0.1 N hydrochloric acid buffer (pH 1.2)**

S. No.	Concentration (µg/ml)	Absorbance* (at 230 nm)
0	0	0
1	5	0.227
2	10	0.406
3	15	0.621
4	20	0.824
5	25	0.957
<b>Correlation Coefficient = 0.998</b>		
<b>Absorbance <math>y = 0.04x + 0.012</math></b>		

It was found that the estimation of Hydrocodone by UV spectrophotometric method at  $\lambda_{\max}$  230.0 nm in 0.1N Hydrochloric acid had good reproducibility and this method was used in the study. The correlation coefficient for the standard curve was found to be closer to 1, at the concentration range, 5- 25 $\mu$ g/ml. The regression equation generated was  $y = 0.04x + 0.012$ .




**Fig 1: standard graph of Hydrocodone in 0.1 N HCl**

**Table 3: Observations for graph of Hydrocodone in pH 6.8 phosphate buffer (234nm)**

Conc [ $\mu$ g/l]	Abs
0	0
2	0.125
4	0.267
6	0.367
8	0.456
10	0.571
12	0.701

It was found that the estimation of Hydrocodone by UV spectrophotometric method at  $\lambda_{\max}$  234.0 nm in 0.1N Hydrochloric acid had good reproducibility and this method was used in the study. The correlation coefficient for the standard curve was found to be closer to 1, at the concentration range, 0- 12 $\mu$ g/ml. The regression equation generated was  $y = 0.056x + 0.014$ .



**Fig 2: Standard graph of Hydrocodone pH 6.8 phosphate buffer (234nm)**

#### Evaluation Parameters for Sustained release Tablets of Hydrocodone:

##### Pre-compression parameters:

**Table 4 Pre-compression parameters**

Formulations	Bulk Density	Tap Density	Carr's Index	Hausner ratio	Angle Of Repose( $\theta$ )
	( $\text{gm}/\text{cm}^3$ )	( $\text{gm}/\text{cm}^3$ )	(%)		
F <sub>1</sub>	0.45	0.55	18.18	1.22	27.91
F <sub>2</sub>	0.47	0.55	14.54	1.17	28.23
F <sub>3</sub>	0.5	0.58	13.79	1.16	29.34
F <sub>4</sub>	0.46	0.55	16.36	1.19	26.71
F <sub>5</sub>	0.5	0.58	13.79	1.16	29.34
F <sub>6</sub>	0.47	0.55	14.54	1.17	28.23
F <sub>7</sub>	0.5	0.58	13.79	1.16	29.34
F <sub>8</sub>	0.41	0.5	18	1.21	26.78
F <sub>9</sub>	0.41	0.5	18	1.21	26.78
F <sub>10</sub>	0.42	0.51	18.24	1.2	26.68
F <sub>11</sub>	0.48	0.56	18.12	1.21	26.7
F <sub>12</sub>	0.41	0.54	18.11	1.22	26.71

**Post-compression parameters:****Table 5: Post-compression parameters**

Formulations	Weight variation (mg)	Hardness (kg/cm <sup>2</sup> )	Thickness (mm)	Friability (%)	Assay (%)
<b>F<sub>1</sub></b>	105	4.5	3.59	0.43	97.23
<b>F<sub>2</sub></b>	104	4.6	3.64	0.34	98.55
<b>F<sub>3</sub></b>	110	4.5	3.59	0.49	98.16
<b>F<sub>4</sub></b>	109	4.6	3.58	0.47	99.34
<b>F<sub>5</sub></b>	99.4	4.3	3.59	0.49	98.16
<b>F<sub>6</sub></b>	102	4.7	3.64	0.34	98.55
<b>F<sub>7</sub></b>	101	4.5	3.59	0.49	98.16
<b>F<sub>8</sub></b>	107	4.6	3.56	0.34	99.25
<b>F<sub>9</sub></b>	102	4.5	3.56	0.34	99.25
<b>F<sub>10</sub></b>	103	4.4	3.55	0.43	98.6
<b>F<sub>11</sub></b>	102.4	4.8	3.45	0.54	98.7
<b>F<sub>12</sub></b>	98.5	4.5	3.54	0.43	98.5

Both the pre and post compression parameters were found to be within the limits


***In vitro* Dissolution studies[6]:**


*In vitro* dissolution studies were carried out by using 900ml of 0.1 N HCl in USP dissolution apparatus 2 hrs after that using 6.8ph phosphate buffer by using

paddle method. The dissolution studies were carried out for about 12hr.


**Table 6: *In vitro* dissolution data**

Time( hrs)	F1	F2	F3	F4	F5	F6	F7	F8	F9	F10	F11	F12
0	0	0	0	0	0	0	0	0	0	0	0	0
0.5	10.46	7.46	6.77	8.54	5.46	9.66	10.79	11.77	8.73	9.75	11.46	13.87
1	20.22	14.26	15.02	17.21	14.66	16.22	21.1	19.5	23.54	16.44	20.74	22.46
2	32.65	20.65	22.55	35.53	28.44	25.45	32.86	31.88	38.33	27.87	31.57	34.78
3	49.68	39.29	40.89	50.12	43.85	46.89	43.24	49.28	44.25	32.44	42.76	46.18
4	55.24	59.55	48.22	68.84	65.88	62.83	66.49	61.11	51.01	39.78	62.15	55.41
6	74.24	80.65	59.77	79.63	96.12	72.7	84.25	82.58	78.98	58.74	85.46	76.15
8	97.55	98.34	74.35	87.46	97.56	89.26	99.96	100.25	96.99	70.84	92.82	82.16
10	97.45	98.24	91.49	98.89	97.34	98.98	99.09	100.76	96.56	81.87	97.46	87.46
12	97.35	97.67	98.43	98.67	97.95	98.33	98.45	99.67	96.18	90.47	97.13	91.16


**Fig 3 : Cumulative drug release of formulations(F1-F3)**



**Fig 4: Cumulative drug release of formulations(F4-F6)**



**Fig 5: Cumulative drug release of formulations(F7-F9)**



**Fig 6: Cumulative drug release of formulations(F10-F12)**

From this dissolution studies it was found that F3 formulation was the best formulation compared to other formulations because f3 formulation shows 98.43% at 12 hrs. This formulation was formulated by using HPMC K15M in the concentration of 10mg. other formulations also shown maximum drug release in 10 hrs like f1, f2, f5, f7, and f9. And f8 formulation 100 % drug release at 10 hrs.

These formulations (f1, f2, f5, f7, f8, f9) had shown maximum drug release in 10hrs only except F3 which has shown desired drug release in 12hrs. So it is considered as the optimised formula

#### Application of Release Rate Kinetics to Dissolution Data:

Various models were tested for explaining the kinetics of drug release. To analyze the mechanism of the drug release rate kinetics of the dosage form, the obtained data were fitted into zero-order, first order, Higuchi, and Korsmeyer-Peppas release model.

**Table 7: Release kinetics data for optimised formulation (F3)**

CUMULATIVE (%) RELEASE Q	TIME ( T )	ROOT ( T )	LOG( %) RELEASE	LOG ( T )	LOG (%) REMAIN
0	0	0			2.000
<b>6.77</b>	30	5.477	0.831	1.477	1.970
<b>15.02</b>	60	7.746	1.177	1.778	1.929
<b>22.55</b>	120	10.954	1.353	2.079	1.889
<b>40.89</b>	180	13.416	1.612	2.255	1.772
<b>48.22</b>	240	15.492	1.683	2.380	1.714
<b>59.77</b>	360	18.974	1.776	2.556	1.605
<b>74.35</b>	480	21.909	1.871	2.681	1.409
<b>91.49</b>	600	24.495	1.961	2.778	0.930
<b>98.43</b>	720	26.833	1.993	2.857	0.196




Fig 7 : Zero order release kinetics graph




Fig 10: First order release kinetics graph




Fig 8 : Higuchi release kinetics graph




Fig 9: Kars Mayer peppas graph

From the above graphs it was evident that the formulation F3 was followed peppas order release kinetics.

### CONCLUSION:

In the present work, an attempt has been made to develop sustained release matrix tablets of Hydrocodone. Different grades of hydroxy propyl methyl cellulose and different grades of eudragit polymers used. All the formulations were prepared by direct compression method using 6mm punch on 8 station rotary tablet punching machine. The blend of all the formulations showed good flow properties such as angle of repose, bulk density, tapped density. The prepared tablets were shown good post compression parameters and they passed all the quality control evaluation parameters as per I.P limits. Among all the formulations F3 formulation showed maximum % drug release i.e., 98.43 % in 12 hrs hence it is considered as optimized formulation. The f3 formulation contains HPMC K15M in the concentration of 10 mg.

### REFERENCES:

1. Sarika Pundir *Et. Al.*, Sustained Release Matrix Technology And Recent Advance In Matrix Drug Delivery System: A Review *Int. J. Drug Res. Tech.* 2013; Vol. 3 (1): 12-20.
2. Ashish *Et Al.* World Journal Of Pharmacy And Pharmaceutical Sciences Sustained Release Matrix Type Drug Delivery System: A Review, 2015; 4(02).
3. Querfurth Hw, Laferla Fm (28 January 2010). "Alzheimer's Disease". *The New England Journal Of Medicine* 362 (4): 329–
44. [Doi:10.1056/Nejmra0909142](https://doi.org/10.1056/Nejmra0909142). [Pmid 20107219](https://pubmed.ncbi.nlm.nih.gov/20107219/).
4. Dr. Patel Bhavik N., Patel Devyani B., Dr. Patel Chhagan N. Formulation And Evaluation Of Modified Release Tablet Of Donepezil

Hydrochloride World Journal Of Pharmaceutical Research ,2015;4( 05).

5.Leon Shargel, Susanna Pong, Andrew B.C., Applied Biopharmaceutics And Pharmacokinetics, Modified-Release Drug Products, Pg 515 Fifth Edition, 2004

6.P. Ramya Deepthi1 \*, Vure Prasad2 , Prakash V Diwan Preparation And In-Vitro Evaluation Of Donepezil Hydrochloride Sustained Release Matrix Tablets Using Non-Gelling Polymer Iosr Journal Of Pharmacy And Biological Sciences (Iosr-Jpbs) E-Issn: 2278-3008, P-Issn:2319-7676. Volume 9, Issue 5 Ver. Iv (Sep -Oct. 2014);83-91

7.P. Bharghava Bhushan Rao, KEV. Nagoji and K. Jayaveera Formulation, In Vitro Evaluation and Comparison of Sustained Release Matrix Tablets of Diclofenac Sodium using Okra Gum as Release Modifier IJAPBC,2012;1(3). [www.ijapbc.com](http://www.ijapbc.com)

8.Roohullah, Zafar Iqbal, Fazli Nasir, Muhammad Akhlaq, Sajid Khan Sadozai, Ibrahim Khadra and Shahida Zakir Preparation and In-vitro Evaluation of Sustained Release Phenytoin Sodium Matrix Tablets Prepared by Co-Evaporation Method Using Different Polymers Middle-East Journal of Scientific Research;2012; 11 (2): 246-252.

9.Rohini Diwedi , S Alexandar And M J N Chandrasekar Preparation And In Vitro Evaluation Of Sustained Release Tablet Formulations Of Metformin Hcl Asian Journal of Pharmaceutical and Clinical Research,2012;5(1).

10.Mohd Abdul Hadi, V. Lokeswara Babu and Narottam Pal Formulation and Evaluation of Sustained Release Matrix Tablets of Glimepiride Based on Combination of Hydrophilic and Hydrophobic Polymers Journal of Applied Pharmaceutical Science,2012; 02 (06): 101-107